Search Results - "YAICI, A"

Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases by Souza, R, Humbert, M, Sztrymf, B, Jais, X, Yaici, A, Le Pavec, J, Parent, F, Herve, P, Soubrier, F, Sitbon, O, Simonneau, G

“…The aim of the present study was to describe a large cohort of fenfluramine-associated pulmonary arterial hypertension (fen-PAH) and its possible prognostic…”
Get full text

Pulmonary veno-occlusive disease by Montani, D, Price, L. C, Dorfmuller, P, Achouh, L, Jais, X, Yaici, A, Sitbon, O, Musset, D, Simonneau, G, Humbert, M

“…Pulmonary veno-occlusive disease (PVOD) is currently classified as a subgroup of pulmonary arterial hypertension (PAH) and accounts for 5-10% of cases…”
Get full text

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension by Humbert, M, Sitbon, O, Yaïci, A, Montani, D, O'Callaghan, D S, Jaïs, X, Parent, F, Savale, L, Natali, D, Günther, S, Chaouat, A, Chabot, F, Cordier, J-F, Habib, G, Gressin, V, Jing, Z-C, Souza, R, Simonneau, G

“…Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674 consecutive adult patients who were prospectively enrolled in the French…”
Get full text

Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension by Degano, B, Yaici, A, Le Pavec, J, Savale, L, Jais, X, Camara, B, Humbert, M, Simonneau, G, Sitbon, O

“…Bosentan has proven 4-month efficacy in patients with HIV-associated pulmonary arterial hypertension (PAH-HIV). Herein, the long-term outcome of unselected…”
Get full text

Pulmonary arterial hypertension due to tumor emboli by Dot, J M, Sztrymf, B, Yaïci, A, Dorfmüller, P, Capron, F, Parent, F, Jaïs, X, Sitbon, O, Simonneau, G, Humbert, M

“…Pulmonary arterial hypertension (PAH) is rare in the presence of malignancy and tumour embolisation is one of several possible pathological mechanisms. We…”
Get more information

Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension by CRACOWSKI, Jean-Luc, CHABOT, François, YAICI, Azzedine, SIMONNEAU, Gerald, HUMBERT, Marc, LABARERE, José, FAURE, Patrice, DEGANO, Bruno, SCHWEBEL, Carole, CHAOUAT, Ari, REYNAUD-GAUBERT, Martine, CRACOWSKI, Claire, SITBON, Olivier

Get full text

Pulmonary Arterial Hypertension in France: Results from a National Registry by Humbert, Marc, Sitbon, Olivier, Chaouat, Ari, Bertocchi, Michele, Habib, Gilbert, Gressin, Virginie, Yaici, Azzedine, Weitzenblum, Emmanuel, Cordier, Jean-Francois, Chabot, Francois, Dromer, Claire, Pison, Christophe, Reynaud-Gaubert, Martine, Haloun, Alain, Laurent, Marcel, Hachulla, Eric, Simonneau, Gerald

“…Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in…”
Get full text

HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era by DEGANO, Bruno, GUILLAUME, Mathilde, SAVALE, Laurent, MONTANI, David, JAÏS, Xavier, YAICI, Azzedine, LE PAVEC, Jérôme, HUMBERT, Marc, SIMONNEAU, Gérald, SITBON, Olivier

“…To examine baseline characteristics and outcome, and to determine variables affecting survival in patients with pulmonary arterial hypertension (PAH)…”
Get full text

Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation by Sztrymf, Benjamin, Coulet, Florence, Girerd, Barbara, Yaici, Azzedine, Jais, Xavier, Sitbon, Olivier, Montani, David, Souza, Rogerio, Simonneau, Gerald, Soubrier, Florent, Humbert, Marc

“…Germline mutations in the gene encoding for bone morphogenetic protein receptor 2 (BMPR2) are a cause of pulmonary arterial hypertension (PAH). We conducted a…”
Get full text

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil by Launay, David, Sitbon, Olivier, Le Pavec, Jérôme, Savale, Laurent, Tchérakian, Colas, Yaïci, Azzedine, Achouh, Lara, Parent, Florence, Jais, Xavier, Simonneau, Gérald, Humbert, Marc

“…Objective. Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in SSc-associated pulmonary arterial hypertension (SSc-PAH) are…”
Get full text

Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome by Hachulla, Eric, Launay, David, Yaici, Azzedine, Berezne, Alice, de Groote, Pascal, Sitbon, Olivier, Mouthon, Luc, Guillevin, Loïc, Hatron, Pierre-Yves, Simonneau, Gérald, Clerson, Pierre, Humbert, Marc

“…Objective. To describe the history of SSc-associated pulmonary arterial hypertension (SSc-PAH) in patients with New York Heart Association (NYHA) functional…”
Get full text

Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension by Terrier, B, Tamby, M C, Camoin, L, Guilpain, P, Broussard, C, Bussone, G, Yaici, A, Hotellier, F, Simonneau, G, Guillevin, L, Humbert, M, Mouthon, L

“…Rationale: Pulmonary arterial hypertension (PAH) may be classified as idiopathic (IPAH) or familial (FPAH) or associated with various conditions and exposures…”
Get full text

Pulmonary arterial hypertension associated with fenfluramine exposure : report of 109 cases. Commentary by WEIR, E. K, OBREZTCHIKOVA, M, HERVE, P, SOUBRIER, F, SITBON, O, SIMONNEAU, G, HONG, Z, SOUZA, R, HUMBERT, M, SZTRYMF, B, JAIS, X, YAICI, A, LE PAVEC, J, PARENT, F

Get full text

Idiopathic pulmonary hypertension: what did we learn from genes? by Sztrymf, Benjamin, Yaïci, Azzedine, Jaïs, Xavier, Sitbon, Olivier, Simonneau, Gerald, Humbert, Marc

“…Pulmonary arterial hypertension (PAH) is an uncommon disorder. PAH can be idiopathic, associated with other conditions or clustered in families. Indeed, at…”
Get more information

Genetics of pulmonary arterial hypertension: recent data and practical applications by Sztrymf, B, Yaici, A, Jaïs, X, Simonneau, G, Sitbon, O, Humbert, M

“…Pulmonary arterial hypertension (PAHT) is defined as an increase of mean pulmonary artery pressure above 25 mmHg at rest, or 30 mmHg on exercise, due to…”
Get more information

Identification des cibles antigéniques et étude de la fonction des anticorps anti-cellules musculaires lisses vasculaires au cours de l’hypertension artérielle pulmonaire idiopathique ou associée à la sclérodermie systémique by Bussone, G., Calzas, C., Tamby, M.C., Sanson, C., Ghazal, K., Weksler, B., Broussard, C., Yaici, A., Guillevin, L., Humbert, M., Mouthon, L.

Get full text

Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design by Cracowski, J L, Yaici, A, Sitbon, O, Reynaud-Gaubert, M, Renversez, J C, Pison, C, Faure, P, Cracowski, C, Chouri, N, Chaouat, A, Chabot, F, Schwedhelm, E, Maas, R, Degano, B, Mornex, J F, Humbert, M

“…Pulmonary arterial hypertension (PAH) is a serious disease. Its prognostic is based on the functional status quantified by the NYHA class and the 6-min walking…”
Get more information

From the authors by Humbert, M., Sitbon, O., Montani, D., Jaïs, X., Yaïci, A., O'Callaghan, D.S., Souza, R., Simonneau, G.

Get full text

Les anticorps anticellules musculaires lisses vasculaires sont présents dans le sérum des patients ayant une sclérodermie systémique et/ou une hypertension artérielle pulmonaire by Sahbatou, Y., Camoin, L., Broussard, C., Yaici, A., Bussone, G., Bérezné, A., Dib, H., Simonneau, G., Guillevin, L., Humbert, M., Mouthon, L.

Get full text

Évaluation du traitement par immunosuppresseurs seuls ou associés à un traitement spécifique dans l'hypertension artérielle pulmonaire associée au lupus et au syndrome de Sharp by Launay, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M.

Get full text